UroGen Pharma(URGN) - 2025 Q4 - Annual Results

Exhibit 99.1 UroGen Announces ZUSDURITM Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results PRINCETON, N.J. March 2, 2026-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided an overview of recent developments. "2025 was a tremendously successful and transform ...